Cite
HARVARD Citation
Sircar, G. et al. (2019). Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply. Rheumatology. pp. 925-926. [Online].